Google's Waymo takes the leap into Europe: robotaxi test run in London.Netflix AI Framework VOID removes objects from videos and adjusts physical effects.A folk musician became a target for AI fakes and a copyright trollAnthropic acquires AI-pharma startup Coefficient Bio for $400 million. The AI news for April 5th, 2026

--- This episode is sponsored by ---

Rocket Routine GmbH
Find our more about our today's sponsor Rocket Routine at
Google's Waymo takes the leap into Europe: robotaxi test run in London.
Source: https://www.heise.de/news/Waymo-in-London-Der-ultimative-Haertetest-fuers-autonome-Fahren-11245886.html?wt_mc=rss.red.ho.themen.k%C3%BCnstliche+intelligenz.beitrag.beitrag
Why did we choose this article?
Waymo testing robotaxis in London has direct implications for everyday transportation, city policy, safety standards, and when/where people will encounter driverless taxis in urban areas.

Netflix AI Framework VOID removes objects from videos and adjusts physical effects.
Source: https://the-decoder.de/netflix-veroeffentlicht-open-source-ki-system-zur-objektentfernung-in-videos/
Why did we choose this article?
An open-source tool that can remove objects and fix resulting physical effects changes what editors, platforms, and malicious actors can do with footage—affecting content production, privacy, and misinformation risks.

A folk musician became a target for AI fakes and a copyright troll
Source: https://www.theverge.com/entertainment/907111/murphy-campbell-folk-music-ai-copyright
Why did we choose this article?
A concrete case of AI-generated fakes and copyright abuse on streaming platforms highlights real risks for creators, platform moderation gaps, and the need for better content provenance and takedown processes.

Anthropic acquires AI-pharma startup Coefficient Bio for $400 million.
Source: https://the-decoder.de/anthropic-uebernimmt-ki-pharma-startup-coefficient-bio-fuer-400-millionen-dollar/
Why did we choose this article?
A major AI company paying $400M for a tiny biotech startup signals rapid consolidation and shows how AI is being deployed and funded in drug discovery—relevant to investors, regulators, and healthcare strategy.

Do you have any questions, comments, or suggestions for improvement? We welcome your feedback at podcast@pickert.de.